When.com Web Search

Search results

  1. Results From The WOW.Com Content Network
  2. Genmab - Wikipedia

    en.wikipedia.org/wiki/Genmab

    Genmab A/S is a Danish biotechnology company, founded in February 1999 by Florian Schönharting, at the time managing director of BankInvest Biomedical venture fund. [7] The company is based in Copenhagen, Denmark – internationally, it operates through the subsidiaries Genmab B.V. in Utrecht, the Netherlands, Genmab U.S., Inc. in Princeton, New Jersey, US, and Genmab K.K. in Tokyo, Japan.

  3. Tisotumab vedotin - Wikipedia

    en.wikipedia.org/wiki/Tisotumab_vedotin

    Tisotumab vedotin was developed by Genmab in Utrecht, the Netherlands, and Copenhagen, Denmark, with the code name TF-011-MMAE. [5] In September 2021, tisotumab vedotin was granted accelerated approval by United States Food and Drug Administration for the use of recurrent or metastatic cervical cancer with disease progression on or after ...

  4. Zalutumumab - Wikipedia

    en.wikipedia.org/wiki/Zalutumumab

    Zalutumumab (proposed trade name HuMax-EGFR) is a fully human IgG1 monoclonal antibody (mAb) directed towards the epidermal growth factor receptor (EGFR). It is a product developed by Genmab in Utrecht, the Netherlands.

  5. AOL latest headlines, entertainment, sports, articles for business, health and world news.

  6. Medarex - Wikipedia

    en.wikipedia.org/wiki/Medarex

    Genmab was founded as a European spin-off of American Biotech company Medarex in February 1999. [10] The company was acquired by Bristol Myers Squibb in 2009 for $2.4 billion, which included $300 million in debt, making the payment to Medarex $2.1 billion. [11] [12]

  7. Daratumumab - Wikipedia

    en.wikipedia.org/wiki/Daratumumab

    Daratumumab was originally developed by Genmab, but it is now being jointly developed by Genmab along with the Johnson & Johnson subsidiary Janssen Biotech, which acquired worldwide commercialization rights to the drug from Genmab. [9] Daratumumab was granted breakthrough therapy drug status in 2013, for multiple myeloma.

  8. Teprotumumab - Wikipedia

    en.wikipedia.org/wiki/Teprotumumab

    It is a human monoclonal antibody developed by Genmab and Roche [4] for tumour treatment but was later researched by River Vision Development Corporation and Horizon Therapeutics to be used for ophthalmic uses. [5] It binds to IGF-1R. [1] Teprotumumab was approved for use in the United States in January 2020.

  9. Japanese crime leader pleads guilty in US to trafficking ...

    www.aol.com/news/japanese-crime-leader-pleads...

    The leader of a Japanese crime syndicate who was charged by U.S. authorities with trafficking nuclear materials from Myanmar pleaded guilty on Wednesday, the U.S. Justice Department said in a ...